Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns
Open Access
- 1 July 2020
- journal article
- review article
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 12, 453-466
Abstract
Narcolepsy is a neurological disorder of the sleep-wake cycle characterized by excessive daytime sleepiness (EDS), cataplexy, nighttime sleep disturbances, and REM-sleep-related phenomena (sleep paralysis, hallucinations) that intrude into wakefulness. Dysfunction of the hypocretin/orexin system has been implicated as the underlying cause of narcolepsy with cataplexy. In most people with narcolepsy, symptom onset occurs between the ages of 10 and 35 years, but because the disorder is underrecognized and testing is complex, delays in diagnosis and treatment are common. Narcolepsy is treated with a combination of lifestyle modifications and medications that promote wakefulness and suppress cataplexy. Treatments are often effective in improving daytime functioning for individuals with narcolepsy, but side effects and/or lack of efficacy can result in suboptimal management of symptoms and, in many cases, significant residual impairment. Additionally, the psychosocial ramifications of narcolepsy are often neglected. Recently two new pharmacologic treatment options, solriamfetol and pitolisant, have been approved for adults, and the indication for sodium oxybate in narcolepsy has been expanded to include children. In recent years, there has been an uptick in patient-centered research, and promising new diagnostic and therapeutic options are in development. This paper summarizes current and prospective pharmacological therapies for treating both EDS and cataplexy, discusses concerns specific to children and reproductive-age women with narcolepsy, and reviews the negative impact of health-related stigma and efforts to address narcolepsy stigma.Keywords
This publication has 116 references indexed in Scilit:
- Stigma as a Fundamental Cause of Population Health InequalitiesAmerican Journal of Public Health, 2013
- Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnanciesJournal of Sleep Research, 2013
- Management of narcolepsy during pregnancySleep Medicine, 2013
- Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered QuestionsFrontiers in Neurology, 2013
- Sodium, Blood Pressure, and Cardiovascular DiseaseCirculation, 2012
- Pitolisant, an Inverse Agonist of the Histamine H3 ReceptorClinical Neuropharmacology, 2012
- Hypocretin/orexin and narcolepsy: new basic and clinical insightsActa Physiologica, 2010
- Changing Stigmatizing Perceptions and Recollections About Mental Illness: The Effects of NAMI’s In Our Own VoiceCommunity Mental Health Journal, 2010
- Health-related quality of life in patients with narcolepsySleep Medicine, 2007
- Health-related stigma: Rethinking concepts and interventions 1Psychology, Health & Medicine, 2006